Adult Dosing
Solid Tumors
- Concomitant therapy with irradiation:
- Carcinoma of the head and neck: 80 mg/kg PO x 1 q3 days
Resistant chronic myelocytic leukemia
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
Renal Dose Adjustment (Based on CrCl)
- 10-50 mL/min: Decrease dose to 50%
- <10 mL/min: Decrease dose to 20%
Hepatic Dose Adjustment
- Hepatic impairment: Dose adjustments not defined
- Do not institute therapy if bone marrow function is markedly depressed as therapy is associated with marrow suppression
- Patients who have received irradiation therapy in the past may have an exacerbation of postirradiation erythema
- Hepatotoxicity and hepatic failure resulting in death have been reported with therapy. Also fatal and nonfatal pancreatitis has occurred in HIV-infected patients during therapy
- Severe peripheral neuropathy has been reported in HIV-infected patients receiving hydroxyurea in combination with antiretroviral agents
- Correct severe anemia before initiating therapy with hydroxyurea
- Elderly patients may be more sensitive to the effects of hydroxyurea, and may require a lower dose regimen
- Myeloproliferative disorders, such as polycythemia vera and thrombocythemia, secondary leukemia may occur with the long term use of hydroxyurea
- Cutaneous vasculitic toxicities, including vasculitic ulcerations and gangrene, have occurred in patients with myeloproliferative disorders during therapy with hydroxyurea. Suspend therapy and institute alternative cytoreductive agents in such conditions
Cautions: Use cautiously in
- Renal impairment
- Long-term use
- Myeloproliferative disorder
- Concurrent myelosuppressive agents
- Interferon use
Pregnancy Category:D
Breastfeeding: Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 10 March 2011). Due to the potential for serious adverse reactions in nursing infants, manufacturer recommends discontinuation of nursing or discontinuation of drug, taking into account the importance of the drug to the mother.
Pricing data from www.DrugStore.com in U.S.A.
- Hydroxyurea 500 MG CAPS [Bottle] (TEVA PHARMACEUTICALS USA)
100 mg = $90.99
300 mg = $251.99 - Droxia 300 MG CAPS [Bottle] (B-M SQUIBB ONCOLOGY/IMMUNOLOGY)
30 mg = $32.99
90 mg = $95.97 - Hydrea 500 MG CAPS [Bottle] (B-M SQUIBB ONCOLOGY/IMMUNOLOGY)
100 mg = $139.08
300 mg = $406.58
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
